While the company reported negative EBITDA of $20.04 million in the last twelve months, Mark Iwicki, CEO of Inhibikase ... PFE) and Longboard Pharmaceuticals' acquisition by Lundbeck A/S.

Matt Stober, CEO of Abzena said ... Mr. Boyd most recently served as Head of Business Development at Longboard Pharmaceuticals, where he was responsible for mergers and acquisitions, transactions ...

Mr. Boyd most recently served as Head of Business Development at Longboard Pharmaceuticals, where he was responsible ... and debt and equity capital markets transactions. Matt Stober, CEO of Abzena ...

While the company reported negative EBITDA of $20.04 million in the last twelve months, Mark Iwicki, CEO ... Arena Pharmaceuticals and contributed to significant corporate transactions, including ...